

Javier Santos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4692957/publications.pdf>

Version: 2024-02-01

84
papers

6,563
citations

81839

39
h-index

64755

79
g-index

87
all docs

87
docs citations

87
times ranked

6042
citing authors

#	ARTICLE	IF	CITATIONS
1	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	0.6	913
2	Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. <i>Gut</i> , 2007, 56, 203-209.	6.1	330
3	Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. <i>Gut</i> , 2014, 63, 262-271.	6.1	322
4	Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. <i>Gut</i> , 2001, 48, 630-636.	6.1	256
5	The role of mast cells in functional GI disorders. <i>Gut</i> , 2016, 65, 155-168.	6.1	251
6	Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. <i>Scientific Reports</i> , 2015, 5, 12693.	1.6	248
7	The Intestinal Microenvironment and Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2016, 150, 1305-1318.e8.	0.6	243
8	Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. <i>Gut</i> , 2013, 62, 1160-1168.	6.1	229
9	Release of mast cell mediators into the jejunum by cold pain stress in humans. <i>Gastroenterology</i> , 1998, 114, 640-648.	0.6	223
10	Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis. <i>Gut</i> , 2010, 59, 12-20.	6.1	191
11	Unstable Composition of the Fecal Microbiota in Ulcerative Colitis During Clinical Remission. <i>American Journal of Gastroenterology</i> , 2008, 103, 643-648.	0.2	175
12	The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated With Mucosal Pathobiology and Clinical Manifestations. <i>American Journal of Gastroenterology</i> , 2012, 107, 736-746.	0.2	169
13	Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH. <i>Digestive Diseases and Sciences</i> , 2002, 47, 208-215.	1.1	165
14	Chronic stress impairs rat growth and jejunal epithelial barrier function: role of mast cells. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G847-G854.	1.6	153
15	Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 277, G391-G399.	1.6	152
16	A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. <i>Advances in Therapy</i> , 2018, 35, 289-310.	1.3	152
17	Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis. <i>Cells</i> , 2019, 8, 135.	1.8	115
18	Maladaptive Intestinal Epithelial Responses to Life Stress May Predispose Healthy Women to Gut Mucosal Inflammation. <i>Gastroenterology</i> , 2008, 135, 163-172.e1.	0.6	112

#	ARTICLE	IF	CITATIONS
19	miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. <i>Gut</i> , 2017, 66, 1537.1-1538.	6.1	105
20	Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet. <i>Gut</i> , 2014, 63, 401-408.	6.1	104
21	Cellular and Molecular Basis of Intestinal Barrier Dysfunction in the Irritable Bowel Syndrome. <i>Gut and Liver</i> , 2012, 6, 305-315.	1.4	95
22	Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. <i>Gut</i> , 2015, 64, 1379-1388.	6.1	94
23	Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 1166-1175.	2.0	88
24	Role of Corticotropin-releasing Factor in Gastrointestinal Permeability. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 033-050.	0.8	84
25	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 909-922.	1.9	81
26	Lessons learned â€” resolving the enigma of genetic factors in IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 77-87.	8.2	76
27	Pathogenesis of irritable bowel syndrome: The mast cell connection. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 129-140.	0.6	74
28	Eosinophils Express Muscarinic Receptors and Corticotropin-Releasing Factor to Disrupt the Mucosal Barrier in Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, 1597-1607.	0.6	68
29	Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction. <i>Psychoneuroendocrinology</i> , 2012, 37, 65-77.	1.3	62
30	The joint power of sex and stress to modulate brainâ€™gutâ€™microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2016, 28, 463-486.	1.6	62
31	Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon. <i>Psychoneuroendocrinology</i> , 2008, 33, 1248-1256.	1.3	61
32	Acute experimental stress evokes a differential genderâ€determined increase in human intestinal macromolecular permeability. <i>Neurogastroenterology and Motility</i> , 2012, 24, 740.	1.6	55
33	Efficacy of Intravenous Cyclosporine for Steroid Refractory Attacks of Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 1995, 20, 285-289.	1.1	53
34	Targeting mast cells in the treatment of functional gastrointestinal disorders. <i>Current Opinion in Pharmacology</i> , 2006, 6, 541-546.	1.7	50
35	Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 53-63.	1.4	47
36	miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. <i>Scientific Reports</i> , 2017, 7, 14680.	1.6	46

#	ARTICLE	IF	CITATIONS
37	Intravenous Cyclosporine for Steroid-Refractory Attacks of Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 1995, 20, 207-210.	1.1	43
38	Intestinal Barrier Function and the Brain-Gut Axis. <i>Advances in Experimental Medicine and Biology</i> , 2014, 817, 73-113.	0.8	43
39	Impaired intestinal gas propulsion in manometrically proven dysmotility and in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2010, 22, 401-e92.	1.6	42
40	Downregulation of mucosal mast cell activation and immune response in diarrhoea-predominant irritable bowel syndrome by oral disodium cromoglycate: A pilot study. <i>United European Gastroenterology Journal</i> , 2017, 5, 887-897.	1.6	40
41	Post-infectious IBS: Defining its clinical features and prognosis using an internet-based survey. <i>United European Gastroenterology Journal</i> , 2018, 6, 1245-1253.	1.6	40
42	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 147-157.	0.2	39
43	Prevalence of Functional Gastrointestinal Disorders in Women Who Report Domestic Violence to the Police. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 436-441.	2.4	35
44	Functional gut disorders or disordered gut function? Small bowel dysmotility evidenced by an original technique. <i>Neurogastroenterology and Motility</i> , 2012, 24, 223.	1.6	34
45	Metabotyping of Biofluids Reveals Stress-Based Differences in Gut Permeability in Healthy Individuals. <i>Journal of Proteome Research</i> , 2009, 8, 4799-4809.	1.8	33
46	Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial. <i>United European Gastroenterology Journal</i> , 2019, 7, 1093-1101.	1.6	33
47	Classification of functional bowel disorders by objective physiological criteria based on endoluminal image analysis. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G413-G419.	1.6	31
48	Neuropharmacology of Stress-Induced Mucosal Inflammation: Implications for Inflammatory Bowel Disease and Irritable Bowel Syndrome. <i>Current Molecular Medicine</i> , 2008, 8, 258-273.	0.6	28
49	Cognitive and hedonic responses to meal ingestion correlate with changes in circulating metabolites. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1806-1814.	1.6	27
50	Adaptation of stress-induced mucosal pathophysiology in rat colon involves opioid pathways. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, G124-G128.	1.6	26
51	Epidemiological and clinical profile of adult patients with <i>Blastocystis</i> sp. infection in Barcelona, Spain. <i>Parasites and Vectors</i> , 2016, 9, 548.	1.0	26
52	Effect of Chicory-derived Inulin on Abdominal Sensations and Bowel Motor Function. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 619-625.	1.1	25
53	Effect of a low-flatulogenic diet in patients with flatulence and functional digestive symptoms. <i>Neurogastroenterology and Motility</i> , 2014, 26, 779-785.	1.6	24
54	<i>Anisakis</i> Simplex-Induced Small Bowel Obstruction After Fish Ingestion: Preliminary Evidence for Response to Parenteral Corticosteroids. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 667-671.	2.4	23

#	ARTICLE	IF	CITATIONS
55	Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report. <i>Advances in Therapy</i> , 2017, 34, 587-598.	1.3	23
56	Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in Diarrhea-Predominant Irritable Bowel Syndrome. <i>Scientific Reports</i> , 2020, 10, 20706.	1.6	21
57	Present and Future Therapeutic Approaches to Barrier Dysfunction. <i>Frontiers in Nutrition</i> , 2021, 8, 718093.	1.6	21
58	Double-balloon jejunal perfusion to compare absorption of vitamin E and vitamin E acetate in healthy volunteers under maldigestion conditions. <i>European Journal of Clinical Nutrition</i> , 2013, 67, 202-206.	1.3	20
59	Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction. <i>Scientific Reports</i> , 2018, 8, 2255.	1.6	18
60	Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2020, 115, 2047-2059.	0.2	16
61	Role of microRNA in IBS with increased gut permeability. <i>Gut</i> , 2010, 59, 710-712.	6.1	12
62	Effect of prucalopride on intestinal gas tolerance in patients with functional bowel disorders and constipation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1457-1462.	1.4	12
63	Immunological Regulation of Intestinal Epithelial Transport. <i>Digestion</i> , 1998, 59, 404-408.	1.2	9
64	Vitamin E and Vitamin E Acetate Absorption from Self-assembly Systems under Pancreas Insufficiency Conditions. <i>Chimia</i> , 2014, 68, 129.	0.3	9
65	Effect of selective CCK ₁ receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 288-293.	1.4	8
66	The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults. <i>Advances in Therapy</i> , 2021, 38, 2054-2076.	1.3	8
67	Mucosal RNA and protein expression as the next frontier in IBS: abnormal function despite morphologically intact small intestinal mucosa. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G701-G719.	1.6	7
68	Eosinophils in the Gastrointestinal Tract: Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction. <i>Cells</i> , 2022, 11, 1644.	1.8	7
69	Consensus document on exclusion diets in irritable bowel syndrome (IBS). <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 806-824.	0.1	6
70	Editorial: A Closer Look at Mucosal Inflammation in Irritable Bowel Syndrome: Sex- and Gender-Related Disparities—Quantity, Quality, or Both?. <i>American Journal of Gastroenterology</i> , 2009, 104, 401-403.	0.2	5
71	Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 325-331.	1.4	5
72	The Intestinal Gas Questionnaire (IGQ): Psychometric validation of a new instrument for measuring gas-related symptoms and their impact on daily life among general population and irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14202.	1.6	5

#	ARTICLE	IF	CITATIONS
73	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8047-8061.	1.6	5
74	Impaired intestinal molecular tightness in the mucosa of irritable bowel syndrome: what are the mediators?. <i>Gut</i> , 2009, 58, 161-162.	6.1	4
75	Su1386 Clinical Benefit and Intestinal Mucosal Transcriptome Modulation After Long-Term Mast Cell Stabilization With Oral Disodium Cromoglycate in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Patients. <i>Gastroenterology</i> , 2015, 148, S-494.	0.6	4
76	Blastocystis sp. Carriage and Irritable Bowel Syndrome: Is the Association Already Established?. <i>Biology</i> , 2021, 10, 340.	1.3	4
77	Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations. <i>Cells</i> , 2022, 11, 2046.	1.8	4
78	A novel distinctive form of identification for differential diagnosis of irritable bowel syndrome, inflammatory bowel disease, and healthy controls. <i>GastroHep</i> , 2020, 2, 193-204.	0.3	3
79	144 Jejunal Mucosal Eosinophils Show Higher Corticotropin-Releasing Hormone Content in Association With Clinical Manifestations in Diarrhea-Prone Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2015, 148, S-38.	0.6	2
80	Consensus document on exclusion diets in irritable bowel syndrome (IBS). <i>Nutricion Hospitalaria</i> , 2018, 35, 1450.	0.2	2
81	Response to Rodrigo et al.. <i>American Journal of Gastroenterology</i> , 2014, 109, 1291-1292.	0.2	1
82	A Fermented Milk Product Containing B. lactis CNCM I-2494 Improves the Tolerance of a Plant-Based Diet in Patients with Disorders of Gut-Brain Interactions. <i>Nutrients</i> , 2021, 13, 4542.	1.7	1
83	Editorial: Human Intestinal Permeability, Mucosal Inflammation and Diet. <i>Frontiers in Nutrition</i> , 2022, 9, 894869.	1.6	1
84	Anemia microcítica secundaria a úlcera anastomótica ileocecal. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 111-112.	0.2	0